Evofem Biosciences (EVFM) Competitors $0.0090 +0.00 (+1.12%) As of 04/17/2025 03:06 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsSustainabilityTrendsBuy This Stock EVFM vs. APM, SONN, KZIA, ALLR, EVOK, PWUP, GLTO, GENE, ONVO, and TTNPShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Aptorum Group (APM), Sonnet BioTherapeutics (SONN), Kazia Therapeutics (KZIA), Allarity Therapeutics (ALLR), Evoke Pharma (EVOK), PowerUp Acquisition (PWUP), Galecto (GLTO), Genetic Technologies (GENE), Organovo (ONVO), and Titan Pharmaceuticals (TTNP). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Aptorum Group Sonnet BioTherapeutics Kazia Therapeutics Allarity Therapeutics Evoke Pharma PowerUp Acquisition Galecto Genetic Technologies Organovo Titan Pharmaceuticals Aptorum Group (NASDAQ:APM) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has more volatility & risk, APM or EVFM? Aptorum Group has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500. Does the media prefer APM or EVFM? In the previous week, Aptorum Group had 7 more articles in the media than Evofem Biosciences. MarketBeat recorded 9 mentions for Aptorum Group and 2 mentions for Evofem Biosciences. Aptorum Group's average media sentiment score of 0.02 beat Evofem Biosciences' score of 0.00 indicating that Aptorum Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Evofem Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor APM or EVFM? Evofem Biosciences received 221 more outperform votes than Aptorum Group when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 68.33% of users gave Aptorum Group an outperform vote. CompanyUnderperformOutperformAptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Evofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% Which has higher valuation and earnings, APM or EVFM? Evofem Biosciences has higher revenue and earnings than Aptorum Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptorum Group$430K10.02-$2.83MN/AN/AEvofem Biosciences$11.39M0.09$52.98M-$0.21-0.04 Is APM or EVFM more profitable? Aptorum Group has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Aptorum Group's return on equity of 0.00% beat Evofem Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aptorum GroupN/A N/A N/A Evofem Biosciences -46.42%-91.97%-61.93% Do institutionals & insiders hold more shares of APM or EVFM? 3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAptorum Group beats Evofem Biosciences on 9 of the 13 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02M$6.46B$5.31B$7.35BDividend YieldN/A3.21%5.45%4.34%P/E Ratio-0.016.9521.9417.82Price / Sales0.09231.01380.6697.73Price / CashN/A65.6738.2534.64Price / Book0.005.936.453.98Net Income$52.98M$143.22M$3.22B$247.81M7 Day PerformanceN/A4.28%5.85%3.19%1 Month PerformanceN/A-13.11%-9.62%-7.70%1 Year PerformanceN/A-8.51%11.79%1.49% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.2276 of 5 stars$0.01+1.1%N/A-41.6%$1.02M$11.39M-0.01120APMAptorum Group1.5502 of 5 stars$0.71-5.3%N/A-85.5%$3.68M$430,000.000.0030Upcoming EarningsGap UpSONNSonnet BioTherapeutics1.6212 of 5 stars$1.20-4.0%$20.00+1,566.7%-30.8%$3.68M$1M0.0010Gap DownKZIAKazia Therapeutics3.3072 of 5 stars$0.71-0.1%$11.50+1,519.7%-12.2%$3.58M$2.31M0.0012Short Interest ↓Gap DownALLRAllarity Therapeutics0.2392 of 5 stars$0.80+0.6%N/A-97.7%$3.53MN/A0.0010EVOKEvoke Pharma0.2 of 5 stars$2.35+4.4%N/A-61.8%$3.51M$10.25M-0.214Analyst ForecastShort Interest ↑Gap DownPWUPPowerUp AcquisitionN/A$0.45-16.5%N/AN/A$3.50MN/A0.00N/AHigh Trading VolumeGLTOGalecto2.2623 of 5 stars$2.55+0.4%$10.00+292.2%-85.7%$3.37MN/A-0.1340GENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050Upcoming EarningsHigh Trading VolumeONVOOrganovo0.3558 of 5 stars$1.96-7.5%N/A-87.0%$3.33M$122,000.00-2.3120Analyst ForecastShort Interest ↑Gap DownTTNPTitan Pharmaceuticals1.3082 of 5 stars$3.64-0.6%N/A-50.3%$3.33M$180,000.00-0.7010Analyst ForecastShort Interest ↓News Coverage Related Companies and Tools Related Companies Aptorum Group Alternatives Sonnet BioTherapeutics Alternatives Kazia Therapeutics Alternatives Allarity Therapeutics Alternatives Evoke Pharma Alternatives PowerUp Acquisition Alternatives Galecto Alternatives Genetic Technologies Alternatives Organovo Alternatives Titan Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EVFM Stock Free EVFM Stock Alerts